NCT00624052
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
See it on ClinicalTrials.gov ↗838 people
43.8%
56.2%
367 womenmiddle line = equal numbers471 men
- Phase
- PHASE3
- Paid for by
- Boehringer Ingelheim
- Finished
- —
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 56.4 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).”
- No breastfeeding moms
Women who were breastfeeding could not join.
“pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“symptomatic congestive heart failure.”
Study titles and rules are shown in their original English.